Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b/2 Study of NXC-201 in Relapsed/Refractory AL Amyloidosis
NCT06097832Phase 2Active, not recruiting
- Sponsor
- Nexcella
- Start
- Jun 2024
- Primary completion
- Dec 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of NXC-201 in light-chain amyloidosis, sponsored by Nexcella. Started Jun 2024; status: active, not recruiting.
02
Drugs
NXC-201
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on NCT06097832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06097832.